Milana V Dolezal, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center - Alta Bates Camp · Eden Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dolezal’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A74043 · Current
Licensed to practise in California · since 2001 · expires 2026-11-30 · Jefferson Medical College of Thomas Jefferson University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$98,744
Medicare paid this office $98,744 for 364 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 207 | $55,114 | $132 |
| Return visit (30+ min) | 219 | $27,079 | $82 |
| New patient visit (60+ min) | 100 | $15,908 | $159 |
Who their Medicare patients are
364 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 15% · Women 68% · Also on Medicaid 14% · Health risk score 1.52. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 69% · Cancer 49% · Chronic kidney disease 29% · Diabetes 23% · Depression 21% · Coronary heart disease 20% · Atrial fibrillation 20% · Heart failure 14% · COPD 14% · Stroke 7% · Dementia 5%.
The office billed $314,488, Medicare allowed $135,457 and paid $98,744; for 926 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 364 | 926 | 76 | 1.52 | $314,488 | $98,744 |
| 2023 | 264 | 742 | 75 | 1.52 | $252,602 | $82,036 |
| 2022 | 181 | 759 | 75 | 1.40 | $195,445 | $72,968 |
| 2021 | 291 | 39,646 | 76 | 1.68 | $2,828,555 | $836,512 |
| 2020 | 299 | 24,746 | 75 | 1.84 | $1,448,704 | $404,912 |
| 2019 | 333 | 45,167 | 75 | 1.95 | $2,445,592 | $649,722 |
| 2018 | 289 | 54,152 | 74 | 1.81 | $1,966,371 | $607,362 |
| 2017 | 351 | 1,331 | 74 | 2.34 | $452,800 | $98,666 |
| 2016 | 308 | 1,143 | 72 | 2.17 | $390,658 | $87,804 |
| 2015 | 336 | 1,171 | 73 | 2.22 | $417,353 | $94,256 |
| 2014 | 274 | 1,053 | 73 | 2.27 | $384,144 | $81,094 |
| 2013 | 257 | 1,044 | 72 | 2.46 | $368,836 | $80,186 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 125 | $40,844 | $126 |
| Return visit (30+ min) | 153 | $21,143 | $76 |
| New patient visit (60+ min) | 130 | $18,840 | $145 |
2022: 3 services
| Return visit (30+ min) | 129 | $26,760 | $87 |
| New patient visit (60+ min) | 151 | $24,173 | $160 |
| Long return visit (40+ min) | 59 | $13,607 | $126 |
2021: 27 services
| Injection, denosumab, 1 mg | 27 | $99,223 | None |
| Return visit (30+ min) | 197 | $52,218 | $117 |
| Long return visit (40+ min) | 85 | $35,915 | $168 |
| Administration of chemotherapy into vein, 1 hour or less | 49 | $27,436 | $152 |
| Injection, pegfilgrastim, 6 mg | 24 | $16,194 | None |
| New patient visit (60+ min) | 31 | $6,241 | $201 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $5,770 | $74 |
| Short return visit (20+ min) | 65 | $5,558 | $77 |
| Transitional care management services for problem of high complexity | 13 | $5,343 | $267 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 36 | $4,232 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $4,225 | $92 |
| Injection of additional new drug or substance into vein | 49 | $3,842 | $17 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 116 | $3,434 | $8 |
| Injection of drug or substance under skin or into muscle | 61 | $2,919 | $13 |
| Administration of chemotherapy into vein, each additional hour | 18 | $2,273 | $32 |
| Injection of drug or substance into vein | 23 | $2,099 | $42 |
| Aspiration of bone marrow sample for diagnosis | 11 | $2,048 | $171 |
| Biopsy of bone marrow | 11 | $988 | $82 |
| Application of on-body injector for under skin injection | 23 | $964 | $20 |
| Injection, palonosetron hcl, 25 mcg | 27 | $762 | None |
| Insertion of needle into vein for collection of blood sample | 68 | $462 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 33 | $151 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $98 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 13 | $47 | None |
| Unclassified drugs | 19 | $39 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 13 | $26 | None |
| Injection, midazolam hydrochloride, per 1 mg | 11 | $5 | None |
2020: 23 services
| Injection, denosumab, 1 mg | 22 | $53,523 | None |
| Return visit (30+ min) | 169 | $35,244 | $96 |
| Long return visit (40+ min) | 56 | $13,269 | $134 |
| Administration of chemotherapy into vein, 1 hour or less | 44 | $12,286 | $146 |
| Injection, pegfilgrastim, 6 mg | 13 | $8,572 | None |
| New patient visit (60+ min) | 26 | $4,842 | $186 |
| Extended patient service without direct patient contact, first hour | 24 | $4,698 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,952 | $94 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $3,329 | $101 |
| Short return visit (20+ min) | 37 | $2,784 | $66 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 29 | $2,064 | $31 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $1,905 | $71 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 101 | $1,900 | $8 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,875 | $65 |
| Injection of drug or substance under skin or into muscle | 50 | $1,761 | $13 |
| Injection of additional new drug or substance into vein | 36 | $1,623 | $17 |
| Injection of drug or substance into vein | 22 | $1,497 | $40 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $976 | $70 |
| Injection, palonosetron hcl, 25 mcg | 24 | $730 | None |
| Application of on-body injector for under skin injection | 12 | $478 | $20 |
| Insertion of needle into vein for collection of blood sample | 46 | $200 | $3 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 21 | $134 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 29 | $58 | None |
2019: 33 services
| Return visit (30+ min) | 168 | $43,036 | $98 |
| Injection, denosumab, 1 mg | 21 | $36,539 | None |
| Administration of chemotherapy into vein, 1 hour or less | 50 | $23,821 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $22,772 | $94 |
| Injection, pegfilgrastim, 6 mg | 12 | $21,351 | None |
| New patient visit (60+ min) | 47 | $9,031 | $192 |
| Long return visit (40+ min) | 41 | $8,191 | $137 |
| Other chemotherapy procedure | 11 | $6,580 | $165 |
| Injection, palonosetron hcl, 25 mcg | 30 | $6,209 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,741 | $182 |
| Short return visit (20+ min) | 60 | $4,682 | $65 |
| Extended patient service without direct patient contact, first hour | 36 | $4,247 | $97 |
| Administration of additional new drug or substance into vein, 1 hour or less | 24 | $4,240 | $71 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 36 | $3,833 | $32 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 114 | $3,409 | $8 |
| Injection of additional new drug or substance into vein | 51 | $3,334 | $17 |
| Administration of chemotherapy into vein, each additional hour | 21 | $2,566 | $31 |
| Injection of drug or substance under skin or into muscle | 43 | $2,351 | $16 |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $2,305 | $37 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,179 | $62 |
| Aspiration of bone marrow sample for diagnosis | 12 | $2,002 | $167 |
| Injection, levoleucovorin, not otherwise specified, 0.5 mg | 11 | $1,361 | None |
| Injection of drug or substance into vein | 22 | $1,337 | $39 |
| Biopsy of bone marrow | 12 | $935 | $78 |
| Application of on-body injector for under skin injection | 12 | $588 | $20 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 18 | $417 | None |
| Insertion of needle into vein for collection of blood sample | 57 | $382 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 36 | $115 | None |
| Infusion, normal saline solution , 1000 cc | 18 | $103 | None |
| Injection, fluorouracil, 500 mg | 12 | $92 | None |
| Unclassified drugs | 18 | $45 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 16 | $22 | None |
| Injection, midazolam hydrochloride, per 1 mg | 12 | $6 | None |
2018: 21 services
| Return visit (30+ min) | 114 | $24,119 | $100 |
| Administration of chemotherapy into vein, 1 hour or less | 34 | $17,411 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $14,941 | $65 |
| Injection, denosumab, 1 mg | 16 | $13,799 | None |
| Long return visit (40+ min) | 83 | $11,459 | $125 |
| Injection, palonosetron hcl, 25 mcg | 12 | $6,632 | None |
| Short return visit (20+ min) | 71 | $6,139 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,501 | $180 |
| Extended patient service without direct patient contact, first hour | 47 | $4,486 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $4,261 | $93 |
| New patient visit (60+ min) | 20 | $3,639 | $182 |
| Administration of additional new drug or substance into vein, 1 hour or less | 12 | $3,066 | $70 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 92 | $2,688 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 17 | $2,326 | $31 |
| Injection of drug or substance under skin or into muscle | 34 | $2,166 | $20 |
| Injection of additional new drug or substance into vein | 31 | $2,137 | $18 |
| Injection of drug or substance into vein | 15 | $992 | $47 |
| Short return visit | 14 | $839 | $42 |
| Insertion of needle into vein for collection of blood sample | 35 | $268 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 15 | $49 | None |
| Unclassified drugs | 12 | $31 | None |
2017: 7 services
| Return visit (30+ min) | 238 | $44,849 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $15,380 | $90 |
| Long return visit (40+ min) | 110 | $12,629 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $10,624 | $177 |
| Short return visit (20+ min) | 53 | $7,627 | $44 |
| New patient visit (60+ min) | 38 | $5,294 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,202 | $63 |
2016: 7 services
| Return visit (30+ min) | 177 | $31,929 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 89 | $23,040 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $8,563 | $171 |
| New patient visit (60+ min) | 51 | $7,248 | $142 |
| Long return visit (40+ min) | 46 | $6,495 | $93 |
| Short return visit (20+ min) | 42 | $5,004 | $44 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $3,906 | $62 |
2015: 7 services
| Return visit (30+ min) | 175 | $27,865 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $22,663 | $89 |
| Long return visit (40+ min) | 129 | $17,840 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 67 | $11,781 | $171 |
| New patient visit (60+ min) | 39 | $5,335 | $137 |
| Short return visit (20+ min) | 58 | $4,839 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $2,663 | $62 |
2014: 6 services
| Return visit (30+ min) | 169 | $28,878 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $21,965 | $89 |
| Long return visit (40+ min) | 80 | $12,141 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,910 | $174 |
| New patient visit (60+ min) | 41 | $5,741 | $140 |
| Short return visit (20+ min) | 58 | $5,399 | $43 |
2013: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $25,559 | $87 |
| Return visit (30+ min) | 149 | $24,891 | $61 |
| Long return visit (40+ min) | 63 | $12,705 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,220 | $168 |
| Short return visit (20+ min) | 43 | $4,315 | $41 |
| New patient visit (60+ min) | 26 | $3,605 | $139 |
Medicaid work
$31 in 2021
Medicaid paid $31 for 14 billed services this clinician did in 2021, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 14 | $31 |
| 2021 | 14 | 1 | 12 | $31 |
| 2020 | 43 | 2 | 13 | $134 |
See the largest Medicaid services in earlier years
2020
| Return visit (30+ min) | 12 | $75 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 31 | $59 |
Drugs they prescribed that Part D paid
$1,060,622
Pharmacies billed $1,060,622 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
488 generic and 141 brand-name prescriptions · $1,060,622 in drug cost · 30 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Verzenio | 14 | $212,916 | $15,208 |
| Brukinsa | 14 | $202,938 | $14,496 |
| Ibrance | 11 | $155,483 | $14,135 |
| Eliquis | 51 | $40,332 | $791 |
| Enoxaparin | 19 | $5,994 | $315 |
See all 18 drugs
| Verzenio | 14 | $212,916 | $15,208 |
| Brukinsa | 14 | $202,938 | $14,496 |
| Ibrance | 11 | $155,483 | $14,135 |
| Eliquis | 51 | $40,332 | $791 |
| Enoxaparin | 19 | $5,994 | $315 |
| Anastrozole | 100 | $2,075 | $21 |
| Exemestane | 13 | $1,510 | $116 |
| Tamoxifen Citrate | 55 | $1,199 | $22 |
| Bicalutamide | 16 | $554 | $35 |
| Prochlorperazine Maleate | 26 | $291 | $11 |
| Mirtazapine | 13 | $267 | $21 |
| Allopurinol | 17 | $246 | $14 |
| Venlafaxine Hcl Er | 13 | $193 | $15 |
| Loperamide | 21 | $170 | $8 |
| Acyclovir | 13 | $142 | $11 |
| Prednisone | 25 | $119 | $5 |
| Ondansetron | 27 | $117 | $4 |
| Sulfamethoxazole-Trimethoprim | 27 | $53 | $2 |
Year by year
| 2024 | 629 | 145 | None | 22% | $1,060,622 |
| 2023 | 459 | 112 | None | None | $786,333 |
| 2022 | 414 | 123 | None | 25% | $485,182 |
| 2021 | 1,344 | 151 | 1% (16) | 38% | $3,097,803 |
| 2020 | 1,337 | 154 | None | 30% | $2,410,391 |
| 2019 | 1,119 | 162 | 1% (14) | 32% | $1,878,020 |
| 2018 | 942 | 203 | 2% (23) | 26% | $1,542,663 |
| 2017 | 1,212 | 172 | 6% (70) | 15% | $1,056,496 |
| 2016 | 1,099 | 156 | 8% (89) | None | $741,509 |
| 2015 | 935 | 158 | 7% (64) | None | $479,674 |
| 2014 | 845 | 142 | 8% (70) | None | $463,238 |
| 2013 | 1,050 | 132 | 9% (98) | None | $462,041 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Verzenio | 16 | $265,328 | $16,583 |
| Brukinsa | 12 | $185,677 | $15,473 |
| Eliquis | 45 | $42,662 | $948 |
| Exemestane | 15 | $4,536 | $302 |
| Anastrozole | 55 | $1,312 | $24 |
| Tamoxifen Citrate | 38 | $750 | $20 |
| Hydroxyurea | 19 | $732 | $39 |
| Ibandronate | 16 | $677 | $42 |
| Ondansetron | 34 | $362 | $11 |
| Acyclovir | 23 | $350 | $15 |
| Prochlorperazine Maleate | 25 | $271 | $11 |
| Dexamethasone | 16 | $264 | $16 |
| Sulfamethoxazole-Trimethoprim | 21 | $257 | $12 |
| Prednisone | 11 | $59 | $5 |
2022: 12 drugs
| Phesgo | 11 | $101,149 | $9,195 |
| Eliquis | 25 | $18,651 | $746 |
| Exemestane | 22 | $6,682 | $304 |
| Anastrozole | 62 | $1,695 | $27 |
| Ibandronate | 19 | $1,072 | $56 |
| Tamoxifen Citrate | 18 | $615 | $34 |
| Letrozole | 14 | $544 | $39 |
| Hydroxyurea | 15 | $529 | $35 |
| Ondansetron | 24 | $281 | $12 |
| Prochlorperazine Maleate | 19 | $250 | $13 |
| Acyclovir | 12 | $161 | $13 |
| Alendronate | 12 | $18 | $2 |
2021: 40 drugs
| Neulasta Onpro | 63 | $432,583 | $6,866 |
| Revlimid | 27 | $425,051 | $15,743 |
| Nerlynx | 13 | $240,671 | $18,513 |
| Aranesp | 39 | $174,340 | $4,470 |
| Ibrance | 12 | $164,441 | $13,703 |
| Keytruda | 15 | $160,109 | $10,674 |
| Verzenio | 13 | $149,476 | $11,498 |
| Xgeva | 45 | $118,591 | $2,635 |
| Abraxane | 15 | $105,711 | $7,047 |
| Perjeta | 15 | $104,486 | $6,966 |
| Herceptin | 17 | $82,044 | $4,826 |
| Imatinib Mesylate | 13 | $60,106 | $4,624 |
| Nplate | 16 | $36,160 | $2,260 |
| Akynzeo | 25 | $24,496 | $980 |
| Creon | 18 | $18,577 | $1,032 |
| Zarxio | 20 | $17,609 | $880 |
| Eliquis | 28 | $17,404 | $622 |
| Prolia | 12 | $17,190 | $1,432 |
| Exemestane | 44 | $10,321 | $235 |
| Levoleucovorin | 15 | $9,797 | $653 |
| Palonosetron | 50 | $9,510 | $190 |
| Oxaliplatin | 18 | $5,131 | $285 |
| Anastrozole | 122 | $4,404 | $36 |
| Gemcitabine | 18 | $3,762 | $209 |
| Tamoxifen Citrate | 65 | $3,027 | $47 |
| Paclitaxel | 20 | $2,632 | $132 |
| Fosaprepitant Dimeglumine | 14 | $2,566 | $183 |
| Ibandronate | 38 | $2,446 | $64 |
| Hydroxyurea | 41 | $1,961 | $48 |
| Letrozole | 43 | $1,932 | $45 |
| Raloxifene | 15 | $1,132 | $75 |
| Carboplatin | 15 | $791 | $53 |
| Acyclovir | 31 | $512 | $17 |
| Ondansetron | 21 | $381 | $18 |
| Dexamethasone | 27 | $359 | $13 |
| Prochlorperazine Maleate | 24 | $349 | $15 |
| Mirtazapine | 14 | $308 | $22 |
| Alendronate | 25 | $177 | $7 |
| Sulfamethoxazole-Trimethoprim | 27 | $121 | $4 |
| Gabapentin | 13 | $102 | $8 |
2020: 33 drugs
| Neulasta Onpro | 58 | $423,715 | $7,305 |
| Kadcyla | 13 | $129,925 | $9,994 |
| Nplate | 32 | $121,497 | $3,797 |
| Verzenio | 13 | $77,645 | $5,973 |
| Aranesp | 16 | $70,641 | $4,415 |
| Erbitux | 12 | $66,576 | $5,548 |
| Xgeva | 21 | $50,536 | $2,406 |
| Imatinib Mesylate | 12 | $44,768 | $3,731 |
| Akynzeo | 51 | $37,475 | $735 |
| Zarxio | 20 | $24,731 | $1,237 |
| Levoleucovorin | 33 | $19,471 | $590 |
| Cyclophosphamide | 17 | $15,492 | $911 |
| Exemestane | 25 | $10,112 | $404 |
| Oxaliplatin | 40 | $8,959 | $224 |
| Eliquis | 14 | $6,797 | $485 |
| Anastrozole | 127 | $4,308 | $34 |
| Fosaprepitant Dimeglumine | 18 | $4,130 | $229 |
| Raloxifene | 26 | $3,018 | $116 |
| Tamoxifen Citrate | 45 | $2,977 | $66 |
| Palonosetron | 27 | $2,350 | $87 |
| Irinotecan | 24 | $2,263 | $94 |
| Hydroxyurea | 41 | $2,255 | $55 |
| Ibandronate | 34 | $2,082 | $61 |
| Letrozole | 40 | $1,505 | $38 |
| Dexamethasone | 47 | $659 | $14 |
| Acyclovir | 45 | $648 | $14 |
| Prochlorperazine Maleate | 39 | $558 | $14 |
| Ondansetron | 21 | $368 | $18 |
| Alendronate | 22 | $254 | $12 |
| Pantoprazole | 18 | $247 | $14 |
| Prednisone | 26 | $138 | $5 |
| Gabapentin | 14 | $126 | $9 |
| Sulfamethoxazole-Trimethoprim | 30 | $104 | $3 |
2019: 31 drugs
| Neulasta | 36 | $229,692 | $6,380 |
| Verzenio | 23 | $203,714 | $8,857 |
| Promacta | 11 | $194,133 | $17,648 |
| Ibrance | 15 | $181,498 | $12,100 |
| Aranesp | 47 | $134,137 | $2,854 |
| Avastin | 23 | $104,272 | $4,534 |
| Xgeva | 26 | $61,170 | $2,353 |
| Creon | 13 | $19,582 | $1,506 |
| Exemestane | 31 | $13,237 | $427 |
| Akynzeo | 18 | $12,945 | $719 |
| Docetaxel | 11 | $12,093 | $1,099 |
| Levoleucovorin | 16 | $7,160 | $447 |
| Xarelto | 12 | $7,103 | $592 |
| Eliquis | 16 | $7,050 | $441 |
| Oxaliplatin | 13 | $4,225 | $325 |
| Anastrozole | 148 | $3,866 | $26 |
| Raloxifene | 18 | $3,404 | $189 |
| Tamoxifen Citrate | 56 | $3,188 | $57 |
| Ibandronate | 25 | $2,232 | $89 |
| Hydroxyurea | 48 | $2,134 | $44 |
| Letrozole | 61 | $1,563 | $26 |
| Leucovorin | 11 | $1,392 | $127 |
| Dexamethasone | 37 | $625 | $17 |
| Prochlorperazine Maleate | 30 | $558 | $19 |
| Ondansetron | 17 | $288 | $17 |
| Acyclovir | 16 | $254 | $16 |
| Pantoprazole | 18 | $175 | $10 |
| Prednisone | 27 | $164 | $6 |
| Alendronate | 17 | $94 | $6 |
| Sulfamethoxazole-Trimethoprim | 15 | $86 | $6 |
| Lorazepam | 12 | $57 | $5 |
2018: 19 drugs
| Ibrance | 26 | $309,851 | $11,917 |
| Tagrisso | 13 | $197,716 | $15,209 |
| Neulasta | 12 | $95,348 | $7,946 |
| Aranesp | 29 | $60,828 | $2,098 |
| Xgeva | 26 | $59,762 | $2,299 |
| Faslodex | 20 | $41,599 | $2,080 |
| Exemestane | 24 | $13,140 | $547 |
| Raloxifene | 26 | $5,288 | $203 |
| Anastrozole | 188 | $4,450 | $24 |
| Tamoxifen Citrate | 107 | $4,142 | $39 |
| Ibandronate | 26 | $2,959 | $114 |
| Hydroxyurea | 39 | $1,573 | $40 |
| Letrozole | 36 | $762 | $21 |
| Dexamethasone | 43 | $313 | $7 |
| Pantoprazole | 12 | $114 | $10 |
| Alendronate | 14 | $110 | $8 |
| Prednisone | 17 | $102 | $6 |
| Prochlorperazine Maleate | 14 | $83 | $6 |
| Lorazepam | 23 | $80 | $3 |
2017: 28 drugs
| Xtandi | 20 | $224,081 | $11,204 |
| Tagrisso | 12 | $173,496 | $14,458 |
| Ibrance | 13 | $141,041 | $10,849 |
| Zytiga | 14 | $136,397 | $9,743 |
| Exemestane | 55 | $26,336 | $479 |
| Enoxaparin | 24 | $14,990 | $625 |
| Creon | 15 | $12,526 | $835 |
| Ibandronate | 33 | $3,682 | $112 |
| Tamoxifen Citrate | 108 | $3,364 | $31 |
| Anastrozole | 183 | $3,362 | $18 |
| Ondansetron | 54 | $916 | $17 |
| Gabapentin | 45 | $882 | $20 |
| Bicalutamide | 23 | $564 | $25 |
| Hydrocodone-Acetaminophen | 24 | $539 | $22 |
| Morphine Sulfate Er | 14 | $476 | $34 |
| Prochlorperazine Maleate | 57 | $353 | $6 |
| Oxycodone | 12 | $308 | $26 |
| Venlafaxine | 24 | $278 | $12 |
| Pantoprazole | 33 | $272 | $8 |
| Dexamethasone | 22 | $271 | $12 |
| Nystatin | 16 | $258 | $16 |
| Lorazepam | 55 | $205 | $4 |
| Prednisone | 27 | $182 | $7 |
| Letrozole | 15 | $156 | $10 |
| Potassium Chloride | 11 | $112 | $10 |
| Amlodipine Besylate | 26 | $105 | $4 |
| Alendronate | 11 | $65 | $6 |
| Levofloxacin | 13 | $55 | $4 |
2016: 24 drugs
| Ibrance | 21 | $219,847 | $10,469 |
| Xtandi | 13 | $119,852 | $9,219 |
| Tarceva | 16 | $116,798 | $7,300 |
| Exemestane | 66 | $19,146 | $290 |
| Enoxaparin | 15 | $8,332 | $555 |
| Xarelto | 23 | $8,101 | $352 |
| Anastrozole | 180 | $3,056 | $17 |
| Tamoxifen Citrate | 95 | $2,279 | $24 |
| Ibandronate | 15 | $2,079 | $139 |
| Morphine Sulfate Er | 12 | $989 | $82 |
| Hydrocodone-Acetaminophen | 22 | $799 | $36 |
| Oxycodone | 29 | $750 | $26 |
| Ondansetron | 56 | $749 | $13 |
| Dexamethasone | 23 | $559 | $24 |
| Bicalutamide | 20 | $546 | $27 |
| Prochlorperazine Maleate | 63 | $450 | $7 |
| Letrozole | 13 | $430 | $33 |
| Venlafaxine | 21 | $332 | $16 |
| Gabapentin | 23 | $312 | $14 |
| Lorazepam | 54 | $216 | $4 |
| Lisinopril | 14 | $123 | $9 |
| Pantoprazole | 18 | $100 | $6 |
| Alendronate | 14 | $80 | $6 |
| Amlodipine Besylate | 16 | $49 | $3 |
2015: 24 drugs
| Ibrance | 14 | $140,561 | $10,040 |
| Tarceva | 20 | $135,172 | $6,759 |
| Exemestane | 53 | $17,314 | $327 |
| Xarelto | 13 | $4,884 | $376 |
| Oxycontin | 11 | $4,133 | $376 |
| Spiriva | 11 | $3,437 | $312 |
| Anastrozole | 204 | $3,195 | $16 |
| Raloxifene | 12 | $2,562 | $214 |
| Tamoxifen Citrate | 86 | $2,456 | $29 |
| Ondansetron | 49 | $1,983 | $40 |
| Bicalutamide | 20 | $808 | $40 |
| Oxycodone | 20 | $655 | $33 |
| Prochlorperazine Maleate | 34 | $391 | $11 |
| Potassium Chloride | 13 | $374 | $29 |
| Megestrol Acetate | 14 | $359 | $26 |
| Venlafaxine | 16 | $339 | $21 |
| Hydrocodone-Acetaminophen | 12 | $328 | $27 |
| Letrozole | 13 | $282 | $22 |
| Warfarin | 22 | $237 | $11 |
| Gabapentin | 14 | $233 | $17 |
| Lorazepam | 30 | $172 | $6 |
| Levofloxacin | 15 | $149 | $10 |
| Dexamethasone | 18 | $131 | $7 |
| Pantoprazole | 18 | $108 | $6 |
2014: 23 drugs
| Nexavar | 11 | $122,073 | $11,098 |
| Tarceva | 17 | $106,441 | $6,261 |
| Enoxaparin | 17 | $21,724 | $1,278 |
| Exemestane | 25 | $11,878 | $475 |
| Xarelto | 14 | $8,503 | $607 |
| Anastrozole | 156 | $3,855 | $25 |
| Tamoxifen Citrate | 88 | $2,763 | $31 |
| Ondansetron | 27 | $1,230 | $46 |
| Hydrocodone-Acetaminophen | 30 | $1,137 | $38 |
| Gabapentin | 14 | $906 | $65 |
| Megestrol Acetate | 17 | $898 | $53 |
| Potassium Chloride | 15 | $772 | $51 |
| Prochlorperazine Maleate | 29 | $418 | $14 |
| Oxycodone | 19 | $359 | $19 |
| Lactulose | 23 | $245 | $11 |
| Pantoprazole | 15 | $178 | $12 |
| Levofloxacin | 12 | $168 | $14 |
| Lorazepam | 23 | $113 | $5 |
| Warfarin | 17 | $112 | $7 |
| Spironolactone | 11 | $94 | $9 |
| Amlodipine Besylate | 12 | $75 | $6 |
| Chlorhexidine Gluconate | 12 | $59 | $5 |
| Clonidine | 13 | $54 | $4 |
2013: 27 drugs
| Gleevec | 13 | $88,743 | $6,826 |
| Neupogen | 23 | $70,780 | $3,077 |
| Tarceva | 11 | $58,519 | $5,320 |
| Enoxaparin | 29 | $35,404 | $1,221 |
| Exemestane | 31 | $13,028 | $420 |
| Cymbalta | 18 | $7,598 | $422 |
| Fondaparinux | 11 | $6,119 | $556 |
| Anastrozole | 138 | $5,206 | $38 |
| Lyrica | 15 | $4,606 | $307 |
| Oxycontin | 19 | $3,798 | $200 |
| Tamoxifen Citrate | 84 | $2,124 | $25 |
| Gabapentin | 29 | $1,819 | $63 |
| Ondansetron | 28 | $1,740 | $62 |
| Potassium Chloride | 36 | $973 | $27 |
| Venlafaxine | 16 | $836 | $52 |
| Oxycodone | 29 | $646 | $22 |
| Hydrocodone-Acetaminophen | 30 | $636 | $21 |
| Pantoprazole | 30 | $545 | $18 |
| Prochlorperazine Maleate | 29 | $360 | $12 |
| Nystatin | 12 | $350 | $29 |
| Letrozole | 15 | $276 | $18 |
| Lorazepam | 47 | $270 | $6 |
| Warfarin | 15 | $176 | $12 |
| Amlodipine Besylate | 21 | $168 | $8 |
| Carisoprodol | 12 | $136 | $11 |
| Clonidine | 14 | $93 | $7 |
| Zolpidem | 11 | $69 | $6 |
Money from drug and device companies
$6,587 in 2025
| 2025 | 20 | 36 | $5,472 | $6,587 |
| 2024 | 10 | 23 | $3,330 | $4,263 |
| 2023 | 13 | 26 | $11,628 | $13,794 |
| 2022 | 13 | 27 | $9,866 | $12,335 |
| 2021 | 26 | 105 | $60,714 | $68,625 |
| 2020 | 24 | 54 | $23,278 | $24,081 |
| 2019 | 28 | 84 | $2,500 | $5,783 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Bayer Healthcare Pharmaceuticals | None | $2,272 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Datroway | $1,248 | 3 payments
|
| Gilead Sciences | Trodelvy | $1,183 | 3 payments
|
| Pfizer | Bosulif | $974 | 2 payments
|
| Stemline Therapeutics | Orserdu | $218 | 2 payments
|
| Celgene | Reblozyl | $201 | 7 payments
|
See all 36 published payments
| Gilead Sciences | Consulting · 2025-12-18 | Trodelvy | $580 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-11-12 | Datroway | $670 |
| Pfizer | Consulting · 2025-11-12 | None | $945 |
| Puma Biotechnology | Meals · 2025-11-11 | Nerlynx | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-06 | Iclusig | $25 |
| Celgene | Meals · 2025-10-24 | Reblozyl | $28 |
| GlaxoSmithKline | Meals · 2025-09-16 | Ojjaara | $29 |
| Celgene | Meals · 2025-09-15 | Opdivo | $33 |
| Kite Pharma | Meals · 2025-08-27 | Yescarta | $22 |
| Stemline Therapeutics | Meals · 2025-08-22 | Orserdu | $68 |
| Stemline Therapeutics | Meals · 2025-08-20 | Orserdu | $150 |
| Celgene | Meals · 2025-08-19 | Reblozyl | $31 |
| Merck Sharp & Dohme | Meals · 2025-08-05 | Keytruda | $28 |
| Celgene | Meals · 2025-06-25 | Reblozyl | $30 |
| Array Biopharma | Meals · 2025-06-13 | Lorbrena | $33 |
| GlaxoSmithKline | Meals · 2025-06-04 | Ojjaara | $20 |
| Bayer Healthcare Pharmaceuticals | Consulting · 2025-05-31 | None | $2,142 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-31 | None | $130 |
| Genentech USA | Meals · 2025-05-28 | Venclexta | $29 |
| Gilead Sciences | Meals · 2025-05-27 | Trodelvy | $23 |
| Gilead Sciences | Consulting · 2025-05-15 | Trodelvy | $580 |
| Kite Pharma | Meals · 2025-05-12 | Yescarta | $16 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-04-21 | None | $23 |
| Janssen Biotech | Education · 2025-04-16 | Darzalex | $99 |
| Tactile Systems Technology | Meals · 2025-04-15 | Flexitouch Plus | $22 |
| SpringWorks Therapeutics | Meals · 2025-04-15 | Ogsiveo | $20 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-04-11 | Datroway | $555 |
| Recordati Rare Diseases Inc. | Meals · 2025-03-24 | Enjaymo | $28 |
| Celgene | Meals · 2025-03-11 | Reblozyl | $26 |
| Rigel Pharmaceuticals | Meals · 2025-02-06 | Tavalisse | $29 |
| Celgene | Meals · 2025-02-04 | Opdivo | $34 |
| Rigel Pharmaceuticals | Meals · 2025-01-28 | Tavalisse | $27 |
| Abbvie | Meals · 2025-01-22 | Epkinly | $22 |
| Pfizer | Meals · 2025-01-13 | Bosulif | $29 |
| Celgene | Meals · 2025-01-09 | Reblozyl | $18 |
| Adc Therapeutics America | Meals · 2025-01-06 | Zynlonta | $19 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $4,263
| AstraZeneca Pharmaceuticals LP | Truqap | $3,559 | 8 payments
|
| Stemline Therapeutics | Orserdu | $177 | 1 payment
|
| Gilead Sciences | Trodelvy | $131 | 1 payment
|
| Puma Biotechnology | None | $109 | 2 payments
|
| Celgene | Reblozyl | $71 | 3 payments
|
| Abbvie | Imbruvica | $69 | 3 payments
|
| Array Biopharma | Xalkori | $56 | 2 payments
|
| GlaxoSmithKline | Jemperli | $32 | 1 payment
|
| Kite Pharma | Yescarta | $32 | 1 payment
|
| Eisai | Lenvima | $29 | 1 payment
|
2023: $13,794
| Seagen | Tukysa | $9,615 | 7 payments
|
| Novartis Pharmaceuticals | Kisqali | $1,838 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Calquence | $1,733 | 3 payments
|
| Gilead Sciences | Trodelvy | $118 | 1 payment
|
| Puma Biotechnology | Nerlynx | $96 | 1 payment
|
| ADC Therapeutics America | None | $86 | 1 payment
|
| Stemline Therapeutics | Orserdu | $80 | 2 payments
|
| Daiichi Sankyo | Injectafer | $67 | 3 payments
|
| Celgene | Reblozyl | $54 | 2 payments
|
| Pfizer | Xtandi | $35 | 2 payments
|
| CTI BioPharma | Vonjo | $28 | 1 payment
|
| Janssen Biotech | Imbruvica | $25 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $19 | 1 payment
|
2022: $12,335
| Lilly USA | Verzenio | $6,250 | 1 payment
|
| Gilead Sciences | Trodelvy | $5,489 | 12 payments
|
| Novocure GmbH | None | $200 | 1 payment
|
| Puma Biotechnology | Nerlynx | $120 | 1 payment
|
| Amgen | Nplate | $49 | 2 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $47 | 2 payments
|
| Janssen Biotech | Imbruvica | $41 | 2 payments
|
| Seagen | Tivdak | $26 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $24 | 1 payment
|
| Novartis Pharmaceuticals | None | $24 | 1 payment
|
| Clovis Oncology | None | $22 | 1 payment
|
| GlaxoSmithKline | Zejula | $22 | 1 payment
|
| Myriad Genetic Laboratories | Precisetumor | $20 | 1 payment
|
2021: $68,625
| Seagen | Tukysa | $28,300 | 20 payments
|
| Puma Biotechnology | Nerlynx | $14,341 | 13 payments
|
| Daiichi Sankyo | Enhertu | $11,338 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $8,915 | 11 payments
|
| Karyopharm Therapeutics | Xpovio | $2,288 | 3 payments
|
| Genzyme | None | $2,280 | 1 payment
|
| Athenex Pharmaceutical Division | None | $350 | 2 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $170 | 10 payments
|
| Pfizer | Inlyta | $140 | 9 payments
|
| Janssen Biotech | Erleada | $67 | 3 payments
|
| Lilly USA | Cyramza | $59 | 2 payments
|
| Pharmacosmos Therapeutics | Monoferric | $41 | 3 payments
|
| Coherus Biosciences | Udenyca | $39 | 1 payment
|
| Incyte | Jakafi | $35 | 2 payments
|
| Celgene | Pomalyst | $32 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $31 | 2 payments
|
| Amgen | Lumakras | $26 | 1 payment
|
| AMAG Pharmaceuticals | Feraheme | $24 | 1 payment
|
| Exelixis | Cabometyx | $22 | 1 payment
|
| AbbVie | Creon | $22 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $21 | 1 payment
|
| Eisai | Lenvima | $21 | 1 payment
|
| BeiGene USA | Brukinsa | $19 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $18 | 1 payment
|
| Astellas Pharma US | Xtandi | $17 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $24,081
| Daiichi Sankyo | Enhertu | $8,139 | 9 payments
|
| Puma Biotechnology | Nerlynx | $5,830 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | None | $4,465 | 2 payments
|
| Seagen | Tukysa | $2,374 | 4 payments
|
| Immunomedics | Trodelvy | $1,750 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $1,012 | 2 payments
|
| Janssen Biotech | Imbruvica | $68 | 5 payments
|
| Exelixis | Cabometyx | $48 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $41 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $39 | 2 payments
|
| Pfizer | Xalkori | $38 | 3 payments
|
| Astellas Pharma US | Padcev | $25 | 1 payment
|
| Lilly USA | Cyramza | $24 | 1 payment
|
| Jazz Pharmaceuticals | Vyxeos | $24 | 1 payment
|
| AbbVie | Venclexta | $24 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $22 | 1 payment
|
| Array Biopharma | Braftovi | $22 | 1 payment
|
| Blueprint Medicines | Ayvakit | $22 | 1 payment
|
| Eisai | Lenvima | $21 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $21 | 1 payment
|
| Amgen | Neulasta | $20 | 1 payment
|
| Mylan Institutional | Ogivri | $20 | 1 payment
|
| Genentech USA | Venclexta | $19 | 1 payment
|
| Aurobindo Pharma USA | Folotyn | $15 | 1 payment
|
2019: $5,783
| Seattle Genetics | Adcetris | $1,749 | 6 payments
|
| Puma Biotechnology | Nerlynx | $1,232 | 6 payments
|
| Daiichi Sankyo | Enhertu | $766 | 5 payments
|
| Novartis Pharmaceuticals | Kisqali | $283 | 5 payments
|
| Sirtex Medical | Sir-Spheres Microspheres | $257 | 1 payment
|
| Janssen Biotech | Erleada | $184 | 9 payments
|
| Exelixis | Cabometyx | $158 | 9 payments
|
| Lilly USA | Verzenio | $156 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $142 | 3 payments
|
| AbbVie | Venclexta | $136 | 1 payment
|
| Celgene | Inrebic | $122 | 3 payments
|
| Amgen | Kyprolis | $77 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $74 | 3 payments
|
| Genzyme | Elitek | $47 | 2 payments
|
| Eisai | Lenvima | $47 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $45 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $42 | 2 payments
|
| Pfizer | Ibrance | $42 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $35 | 2 payments
|
| Incyte | Jakafi | $34 | 2 payments
|
| Servier Pharmaceuticals | Oncaspar | $24 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $24 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $22 | 1 payment
|
| Genentech USA | Gazyva | $21 | 1 payment
|
| Clovis Oncology | Rubraca | $19 | 2 payments
|
| Verastem | Copiktra | $17 | 1 payment
|
| Spectrum Pharmaceuticals | Folotyn | $16 | 1 payment
|
| Astellas Pharma US | Padcev | $15 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme Corporation · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2021 | Their institution | $2,821 |
| Novartis Pharmaceuticals Corporation · An Open Label Multicenter Phase Iiib Study of Ribociclib Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Hr Her2 Negative Her2 Advanced Breast Cancer Abc Who Received No Prior Hormonal Therapy · 2019 | Their institution | $1,244 |
| Merck Sharp & Dohme LLC · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2023 | Their institution | $435 |
| Merck Sharp & Dohme LLC · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2022 | Their institution | $150 |
Professional record
- NPI
- 1174777643
- Licence
- CA A74043California A74043: Current · expires 2026-11-30
- Trained
- Jefferson Medical College of Thomas Jefferson University, 1999
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Federal specialty code 174400000X (174400000X); Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2008-11-11
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2001 Dwight Way, Berkeley, CA, 94704